Cryo-Shocked Dead Cells for Targeted AML Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) face challenges such as frequent disease relapse after chemotherapy and high risks associated with hematopoietic stem cell transplantation, necessitating new strategies for effective treatment.
Innovation Solution
Development of a composition comprising cryo-shocked dead cells that maintain their structure and chemotaxis, which can be loaded with chemotherapeutic agents for targeted drug delivery and serve as a cancer vaccine to promote an immune response, utilizing the cells' natural bone marrow homing capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat AML, then remission can be achieved, but disease relapse frequently occurs
Solution Approach 1:
The patent applies preliminary action by using cryo-shocked dead cancer cells as a vaccine before or during chemotherapy treatment. These pre-treated cells are loaded with chemotherapeutic agents and administered to prime the immune system, creating a preliminary immune response that persists after chemotherapy-induced remission, thereby preventing relapse
Solution Approach 2:
The patent uses cryo-shocked dead cancer cells as an intermediary between the chemotherapeutic agent and the immune system. These cells serve as carriers that deliver chemotherapy while simultaneously acting as vaccine antigens, mediating both direct cytotoxic effects and immune system activation to achieve lasting remission
2Reliability
If hematopoietic stem cell transplantation is performed, then curative treatment can be achieved, but transplantation-related mortality is high
Solution Approach 1:
The patent uses copying by creating immunogenic copies of cancer cells through cryo-shock treatment. Instead of using actual living cancer cells or stem cell transplantation, the invention uses dead, cryo-treated cell copies that retain structural features and antigens necessary for immune recognition but lack pathogenicity, thereby achieving curative immunity without transplantation risks
Solution Approach 2:
The patent employs disposable dead cancer cells as a therapeutic vehicle. These cryo-shocked cells are designed to be transient - they deliver their therapeutic function (immune priming and drug delivery) and then are naturally cleared by the immune system, eliminating the long-term risks associated with stem cell transplantation while providing curative benefits
3Ease of operation
If live cancer cells are used for drug delivery, then targeted delivery can be achieved, but pathogenicity remains a risk
Solution Approach 1:
The patent applies taking out by extracting the pathogenicity from cancer cells while retaining their useful properties. Through cryo-shock treatment, the live cancer cells are transformed into dead cells that have lost their ability to proliferate and cause disease, but still maintain their structural features, surface receptors, and chemotaxis capabilities necessary for targeted drug delivery to bone marrow
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cryo-shocked dead cells effectively deliver chemotherapy to bone marrow, stimulate an immune response, and prolong survival in AML models, offering a safer and more targeted approach compared to traditional treatments.
Implementation Method 1
The cells may be cryo-shocked in liquid nitrogen, preferably eliminating the pathogenicity of the dead cells
Implementation Method 2
the dead cells maintain their chemotaxis towards a specific tissue
Data Source
AI summary
Provided herein are methods and compositions related to cryo-shocked cells useful as therapeutic agents. The cryo-shocked cells may be formulated as a vaccine. Disclosed are methods of preparing dead cryo-shocked cells. Disclosed are also methods of treating or preventing cancer, comprising administering the cryo-shocked cells. Further, methods for delivering a drug to a target tissue of a patient are disclosed.